Relmada Therapeutics (RLMD) Tops Q1 EPS by 26c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.72), $0.26 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance